Through TrialHub's data intelligence gathering platform, EmVenio can easily identify optimal markets to attract clinical trial participants who are needed to support pharmaceutical sponsors and clinical research organizations' participation goals.

TrialHub's benchmarking and data provide a 360‐degree feasibility overview of the clinical research landscape, allowing EmVenio to strategically select clinical trial site locations based on disease prevalence, recruitment rates, and access to readily available healthcare facilities and practitioners, including underserved communities.

"With TrialHub's uniquely curated data, EmVenio can connect CROs and sponsors to the appropriate population of potential trial participants for a range of studies across a wide array of therapeutic areas," said Thad Wolfram, EmVenio Research president. "Faster and more intelligent access to data allows us to quickly identify and recommend the best communities in which to conduct a trial and activate it in a more efficient manner, saving our clients time and money and providing them the results they need sooner than later."

By working with TrialHub, EmVenio will donate a full patient scholarship to the European Patients' Academy on Therapeutic Innovation's Patient Expert program. EUPATI's program focuses on education, inclusivity and stakeholder partnership to enhance patient engagement through accessible and innovative education.

"We are delighted to welcome EmVenio on board and help their dedicated team of experts expand clinical trial access to underrepresented and underserved patient communities," said Ralitsa Vaskova, Head of Operations at TrialHub. "An organization of true patient champions, recently EmVenio achieved over 44% diversity in infectious disease studies by providing convenient access to clinical research sites. Thanks to rich, pre-validated and pre-qualified data sources and our NLP and AI algorithms, TrialHub now helps EmVenio identify the best sites to support their mission."